10-K: Tarsus Pharmaceuticals Reports Strong XDEMVY Sales in 2024, Eyes European Approval and Lyme Disease Partnership

Tarsus Pharmaceuticals' 10-K filing highlights successful XDEMVY launch with $180.1 million in sales, expansion plans in Europe and Japan, and a potential partnership for its Lyme disease program.

Summary

• Tarsus Pharmaceuticals reported $180.1 million in net product sales for XDEMVY in 2024, its first full year on the market.
• Over 163,000 bottles of XDEMVY were dispensed to patients, and more than 15,000 eye care providers have prescribed it.
• The company has secured broad commercial and Medicare coverage, extending to over 90% of covered lives as of February 25, 2025.
• Tarsus is pursuing European regulatory approval for a preservative-free formulation of XDEMVY, with potential approval expected in 2027.
• In Japan, the company plans to share results from a Demodex blepharitis prevalence study in the first half of 2025 and meet with regulatory authorities.
• The company is seeking a partner for its TP-05 Lyme disease prevention program after positive Phase 2a results.
• Tarsus plans to initiate a Phase 2 study for TP-04 in Ocular Rosacea in the second half of 2025.
• The company incurred a net loss of $115.6 million in 2024, compared to a net loss of $135.9 million in 2023.
• Tarsus believes its existing cash, cash equivalents, and marketable securities of $291.4 million as of December 31, 2024, are sufficient to fund operations for at least the next twelve months.
• The company is expanding its sales force and implementing a direct-to-consumer marketing campaign to increase awareness and adoption of XDEMVY.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While the company shows strong revenue growth and progress in its pipeline, it also reports a significant net loss and faces various risks and uncertainties. The overall outlook is cautiously optimistic.

Positives

• Successful commercial launch of XDEMVY with significant sales and market penetration.
• Positive clinical trial results for XDEMVY in MGD patients with Demodex blepharitis.
• Positive topline results from the Galatea trial for TP-04 in rosacea.
• Positive topline results from the Carpo trial for TP-05 in Lyme disease prevention.
• FDA agreement on the approach for a Phase 2b clinical trial for TP-05.
• Strong cash position to fund operations for the next twelve months.
• Potential for European regulatory approval of XDEMVY in 2027.
• Acceptance of New Drug Application by Chinese regulatory agency for TP-03 for Demodex blepharitis.

Negatives

• The company incurred a net loss of $115.6 million in 2024.
• Reliance on third parties for manufacturing and supply of XDEMVY and product candidates.
• Competition from other companies developing therapies for blepharitis and related conditions.
• The sizes of the market opportunity for XDEMVY for the treatment of Demodex blepharitis, as well as our other product or product candidates, have not been established with precision and may be smaller than we estimate, possibly materially.

Risks

• Dependence on the successful commercialization of XDEMVY and the development of other product candidates.
• Potential competition from existing and new therapies.
• Difficulties in managing growth and expanding operations.
• Reliance on third parties for clinical trials and manufacturing.
• Failure to obtain and maintain sufficient intellectual property protection.
• Product liability lawsuits.
• Misconduct by employees or third parties.
• Health epidemics affecting clinical trials and supply chains.
• Cybersecurity breaches and data loss.
• Unfavorable global and geopolitical economic conditions.
• Delays in clinical trials or failure to meet safety or efficacy endpoints.

Future Outlook

Tarsus anticipates potential European regulatory approval of a preservative-free formulation of XDEMVY in 2027 and plans to initiate a Phase 2 study for TP-04 in Ocular Rosacea in the second half of 2025. The company is also seeking a partner for its TP-05 Lyme disease prevention program.

Management Comments

• XDEMVY has delivered remarkable results for patients and ECPs, and offers a compelling value proposition for payers.
• OR is our next opportunity to create another potential blockbuster market in eye care.
• We continue to believe that the best approach to potentially deliver this potential prophylactic therapy to patients is to enter into discussions to partner this program either prior to the initiation of the Phase 2b study or after the completion of the study.

Industry Context

The announcement reflects a growing focus on addressing root causes of eye diseases and expanding treatment options in the eye care market. Tarsus's approach aligns with the industry's trend towards developing targeted therapies with novel mechanisms of action.

Comparison to Industry Standards

• Azura Ophthalmics, Aperta Biosciences, LLC, Formosa Pharmaceuticals, Inc., Glaukos Corp., Hovione Scientia, Nicox, Premark Pharma, Quorum Innovations, and Viatris are also developing potential prescription therapies for blepharitis.
• Azura Ophthalmics, Aperta Biosciences, LLC, Atticus Medical, and Glaukos Corp. are the only companies currently focused on Demodex blepharitis and are in pre-clinical stage for the Demodex blepharitis indication (Aperta, Atticus, and Glaukos have publicly disclosed plans to initiate Phase 2 trials in 2025), and Premark Pharma, Azura Ophthalmics, Nicox, and Viatris are the only companies with blepharitis programs that have completed Phase 2 trials.

Management Changes

Related Party Transactions

• Equity investment in a privately-held eye care company where certain Tarsus executives and directors are also involved.
• Consulting agreement with a board member who was appointed in December 2021.

Stakeholder Impact

• Shareholders: Potential for long-term growth and value creation, but also risk of stock price volatility and dilution.
• Employees: Continued employment and potential for career advancement, but also risk of job loss due to business challenges.
• Customers: Access to a new treatment option for Demodex blepharitis and potential for future treatments for other conditions.
• Suppliers: Continued business relationship with Tarsus, but also risk of contract termination or renegotiation.
• Creditors: Repayment of debt obligations, but also risk of default or restructuring.

Next Steps

• Continue to accelerate the launch trajectory of XDEMVY.
• Pursue a potentially transformative opportunity in Ocular Rosacea.
• Continue to advance and expand our pipeline, bringing novel products utilizing lotilaner to unmet needs across human medicine, including Lyme disease prophylaxis.
• Evaluate and strategically enter collaborations to maximize the potential of our pipeline and the scope of our eye care product offerings.
• Continue innovating and planning for growth.

Key Dates